A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 02 Dec 2017
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 14 Nov 2017 Planned End Date changed from 14 Feb 2020 to 12 Aug 2020.
- 14 Nov 2017 Status changed from not yet recruiting to recruiting.
- 22 Sep 2017 Planned initiation date changed from 12 May 2017 to 29 Dec 2017.